Human Molecular Genetics · 2014 · 91 citations · 38 references
Life SciencesNeurosciencePharmacologyDrug DesignDrug DiscoveryMolecular NeuroscienceMolecular Basis Of NeurodegenerationNeurodegenerative Disease PharmacologyNeurodegenerative Disease PharmacotherapyParkinson DiseaseParkinsonian DisordersSmall Gtpase SignalingComputer-aided Drug DiscoveryLeucine-rich Repeat DomainsLeucine-rich Repeat Receptor-like KinasesLrrk2 MutationsParkinson's Disease ModelsParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease Treatment
Mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant Parkinson's disease (PD) and contribute to sporadic PD. LRRK2 contains Guanosine-5'-triphosphate (GTP) binding, GTPase and kinase activities that have been implicated in the neuronal degeneration of PD pathogenesis, making LRRK2, a potential drug target. To date, there is no disease-modifying drug to slow the neuronal degeneration of PD and no published LRRK2 GTP domain inhibitor. Here, the biological functions of two novel GTP-binding inhibitors of LRRK2 were examined in PD cell and mouse models. Through a combination of computer-aided drug design (CADD) and LRRK2 bio-functional screens, two novel compounds, 68: and 70: , were shown to reduce LRRK2 GTP binding and to inhibit LRRK2 kinase activity in vitro and in cultured cell assays. Moreover, these two compounds attenuated neuronal degeneration in human SH-SY5Y neuroblastoma cells and mouse primary neurons expressing mutant LRRK2 variants. Although both compounds inhibited LRRK2 kinase activity and reduced neuronal degeneration, solubility problems with 70: prevented further testing in mice. Thus, only 68: was tested in a LRRK2-based lipopolysaccharide (LPS)-induced pre-inflammatory mouse model. 68: reduced LRRK2 GTP-binding activity and kinase activity in brains of LRRK2 transgenic mice after intraperitoneal injection. Moreover, LPS induced LRRK2 upregulation and microglia activation in mouse brains. These findings suggest that disruption of GTP binding to LRRK2 represents a potential novel therapeutic approach for PD intervention and that these novel GTP-binding inhibitors provide both tools and lead compounds for future drug development.
38
Scalable molecular dynamics with NAMD
J. C. Phillips, Rosemary Braun, Wei Wang et al. · Journal of Computational Chemistry · 2005 · 17.4K citations · Full text
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Alexander Zimprich, Saskia Biskup, Petra Leitner et al. · Neuron · 2004 · 3.1K citations · Full text
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Coro Paisán-Ruı́z, Shushant Jain, E. Whitney Evans et al. · Neuron · 2004 · 2.4K citations · Full text
Michael K. Lee, Wanda L.H. Stirling, Yanqun Xu et al. · Proceedings of the National Academy of Sciences · 2002 · 840 citations · Full text